Idorsia Ltd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a CHF5.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors tied to daridorexant’s recent pediatric data and broader commercial potential. He highlights that the Phase 2 trial in children and adolescents with insomnia showed a clear, dose-related increase in total sleep time from the very first day, along with consistent benefits across both objective sleep measurements and patient- or caregiver‑reported outcomes, while maintaining a safety profile comparable to placebo, even at the adult dose.
He also underscores that these results hint at a wider role for orexin pathway modulation in neurodevelopmental conditions such as ADHD and autism, where sleep problems are common and current treatments—especially stimulants—carry safety concerns and strict scheduling. Given the multi‑billion‑dollar ADHD market, the large and growing autism population, and the potential for daridorexant to address insomnia within these groups and thereby substantially enlarge Idorsia’s addressable market, Selvaraju sees meaningful long‑term revenue upside that supports his Buy rating and CHF5, 12‑month price target.